{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:29:42Z","timestamp":1785284982214,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharmaceutical Industries Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001782","name":"The University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Australian Government Research Training Program Scholarship"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biotechnology Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.btre.2019.e00372","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T14:50:44Z","timestamp":1566658244000},"page":"e00372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Production of metabolites of the anti-cancer drug noscapine using a P450BM3 mutant library"],"prefix":"10.1016","volume":"24","author":[{"given":"Luke","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Jarrold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bowser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally L.","family":"Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.btre.2019.e00372_bib0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41570-018-0055-1","article-title":"Extending the application of biocatalysis to meet the challenges of drug development","volume":"2","author":"Devine","year":"2018","journal-title":"Nat. Rev. Chem."},{"issue":"15","key":"10.1016\/j.btre.2019.e00372_bib0010","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1021\/jm501180v","article-title":"Progress toward the development of noscapine and derivatives as anticancer agents","volume":"58","author":"DeBono","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.btre.2019.e00372_bib0015","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1073\/pnas.95.4.1601","article-title":"Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells","volume":"95","author":"Ye","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.btre.2019.e00372_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0041-008X(61)90013-8","article-title":"Toxicity studies on noscapine","volume":"3","author":"Winter","year":"1961","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4-5","key":"10.1016\/j.btre.2019.e00372_bib0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002620000109","article-title":"Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses","volume":"49","author":"Ke","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"issue":"12","key":"10.1016\/j.btre.2019.e00372_bib0030","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cmdc.201200365","article-title":"Synthesis and biological evaluation of N-substituted noscapine analogues","volume":"7","author":"DeBono","year":"2012","journal-title":"ChemMedChem"},{"issue":"10","key":"10.1016\/j.btre.2019.e00372_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077970","article-title":"Rational design, synthesis, and biological evaluation of third generation alpha-noscapine analogues as potent tubulin binding anti-cancer agents","volume":"8","author":"Manchukonda","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.btre.2019.e00372_bib0040","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1124\/mol.105.021899","article-title":"Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma","volume":"69","author":"Aneja","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.btre.2019.e00372_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1124\/mol.63.4.799","article-title":"Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation","volume":"63","author":"Zhou","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"23","key":"10.1016\/j.btre.2019.e00372_bib0050","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1021\/jm050674q","article-title":"Identification of novel and improved antimitotic agents derived from noscapine","volume":"48","author":"Anderson","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.btre.2019.e00372_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/cctc.201801829","article-title":"P450 Monooxygenases Enable Rapid Late-Stage Diversification of Natural Products via C\u2212H Bond Activation","author":"Fessner","year":"2019","journal-title":"ChemCatChem"},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/00498257909038719","article-title":"Metabolic fate of noscapine. II. Isolation and identification of novel metabolites produced by C-C bond cleavage","volume":"9","author":"Tsunoda","year":"1979","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.btre.2019.e00372_bib0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/00498258109045268","article-title":"Metabolic fate of noscapine.; III. Further studies on identification and determination of the metabolites","volume":"11","author":"Tsunoda","year":"2008","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.btre.2019.e00372_bib0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1476-5381.2012.02067.x","article-title":"Metabolic map and bioactivation of the anti-tumour drug noscapine","volume":"167","author":"Fang","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.btre.2019.e00372_bib0075","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1039\/c0cc03165h","article-title":"Cytochromes P450 as useful biocatalysts: addressing the limitations","volume":"47","author":"O\u2019Reilly","year":"2011","journal-title":"Chem. Commun. (Camb.)"},{"issue":"16","key":"10.1016\/j.btre.2019.e00372_bib0080","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1016\/S0021-9258(17)38369-2","article-title":"Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium","volume":"261","author":"Narhi","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jbiotec.2007.01.013","article-title":"Development of a fed-batch process for the production of the cytochrome P450 monooxygenase CYP102A1 from Bacillus megaterium in E. Coli","volume":"129","author":"Pflug","year":"2007","journal-title":"J. Biotechnol."},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00775-006-0188-4","article-title":"Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes","volume":"12","author":"Nardo","year":"2007","journal-title":"JBIC J. Biol. Inorg. Chem."},{"issue":"12","key":"10.1016\/j.btre.2019.e00372_bib0095","doi-asserted-by":"crossref","first-page":"15901","DOI":"10.3390\/ijms131215901","article-title":"Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites","volume":"13","author":"Di Nardo","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0100","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1039\/C1CS15192D","article-title":"P450(BM3) (CYP102A1): connecting the dots","volume":"41","author":"Whitehouse","year":"2012","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.btre.2019.e00372_bib0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10295-004-0202-1","article-title":"Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli","volume":"32","author":"Vail","year":"2005","journal-title":"J. Ind. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0110","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/JB.119.3.736-747.1974","article-title":"Culture medium for enterobacteria","volume":"119","author":"Neidhardt","year":"1974","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.btre.2019.e00372_bib0115","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature","volume":"239","author":"Omura","year":"1964","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.btre.2019.e00372_bib0120","doi-asserted-by":"crossref","DOI":"10.1111\/j.1432-1033.1967.tb00090.x","article-title":"Conversion of P-450 to P-420 by neutral salts and some other reagents","volume":"1","author":"Imai","year":"1967","journal-title":"Eur. J. Biochem."},{"issue":"25","key":"10.1016\/j.btre.2019.e00372_bib0125","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/acs.biochem.6b00183","article-title":"Effect of mutation and substrate binding on the stability of cytochrome P450BM3 variants","volume":"55","author":"Geronimo","year":"2016","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.btre.2019.e00372_bib0130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.btre.2019.e00372_bib0135","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1046\/j.1432-1327.2001.02212.x","article-title":"Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons","volume":"268","author":"Carmichael","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"1-2","key":"10.1016\/j.btre.2019.e00372_bib0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0167-4838(00)00268-5","article-title":"Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant","volume":"1545","author":"Li","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.btre.2019.e00372_bib0145","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1021\/bi962826c","article-title":"A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation","volume":"36","author":"Oliver","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.btre.2019.e00372_bib0150","series-title":"Biocatalysis with Cytochrome P450 Monooxygenases: Towards Selective Oxidation of Terpenes and Fatty Acids","author":"Budde","year":"2007"},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1021\/jm0609061","article-title":"Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis","volume":"50","author":"van Vugt-Lussenburg","year":"2007","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.btre.2019.e00372_bib0160","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1124\/dmd.111.039461","article-title":"Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space","volume":"39","author":"Reinen","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.btre.2019.e00372_bib0165","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/1522-2675(200208)85:8<2458::AID-HLCA2458>3.0.CO;2-L","article-title":"A convenient synthesis of aryl-substituted N-Carbamoyl\/N-Thiocarbamoyl narcotine and related compounds","volume":"85","author":"Aggarwal","year":"2002","journal-title":"Helv. Chim. Acta"},{"issue":"7","key":"10.1016\/j.btre.2019.e00372_bib0170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/dta.46","article-title":"Validated stability-indicating TLC method for the determination of noscapine","volume":"1","author":"Ashour","year":"2009","journal-title":"Drug Test. Anal."},{"issue":"11-12","key":"10.1016\/j.btre.2019.e00372_bib0175","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ccr.2012.01.016","article-title":"Recent density functional theory model calculations of drug metabolism by cytochrome P450","volume":"256","author":"Li","year":"2012","journal-title":"Coord. Chem. Rev."},{"issue":"9","key":"10.1016\/j.btre.2019.e00372_bib0180","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1021\/jm00113a028","article-title":"Determination of the mechanism of demethylenation of (methylenedioxy) phenyl compounds by cytochrome P450 using deuterium isotope effects","volume":"34","author":"Fukuto","year":"1991","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.btre.2019.e00372_bib0185","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/03602532.2015.1086781","article-title":"Carbon-carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes","volume":"47","author":"Bolleddula","year":"2015","journal-title":"Drug Metab. Rev."},{"issue":"28","key":"10.1016\/j.btre.2019.e00372_bib0190","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/S0040-4039(01)88165-X","article-title":"The enzymatic oxidation of isoquinoline alkaloids","volume":"10","author":"Inubushi","year":"1969","journal-title":"Tetrahedron Lett."},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0195","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bbrc.2006.05.179","article-title":"Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3","volume":"346","author":"van Vugt-Lussenburg","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"22","key":"10.1016\/j.btre.2019.e00372_bib0200","doi-asserted-by":"crossref","first-page":"23287","DOI":"10.1074\/jbc.M401717200","article-title":"A single mutation in cytochrome P450 BM3 induces the conformational rearrangement seen upon substrate binding in the wild-type enzyme","volume":"279","author":"Joyce","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"35","key":"10.1016\/j.btre.2019.e00372_bib0205","doi-asserted-by":"crossref","first-page":"25387","DOI":"10.1074\/jbc.M113.479717","article-title":"Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias","volume":"288","author":"Butler","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"40","key":"10.1016\/j.btre.2019.e00372_bib0210","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1039\/c1dt10098j","article-title":"Structure, electronic properties and catalytic behaviour of an activity-enhancing CYP102A1 (P450(BM3)) variant","volume":"40","author":"Whitehouse","year":"2011","journal-title":"Dalton Trans."},{"issue":"42","key":"10.1016\/j.btre.2019.e00372_bib0215","doi-asserted-by":"crossref","first-page":"15039","DOI":"10.1002\/chem.201502020","article-title":"Drug oxidation by cytochrome P450BM3 : metabolite synthesis and discovering new P450 reaction types","volume":"21","author":"Ren","year":"2015","journal-title":"Chemistry"},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/prot.24985","article-title":"Insights into regioselective metabolism of mefenamic acid by cytochrome P450 BM3 mutants through crystallography, docking, molecular dynamics, and free energy calculations","volume":"84","author":"Capoferri","year":"2016","journal-title":"Proteins"},{"key":"10.1016\/j.btre.2019.e00372_bib0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.abb.2015.12.005","article-title":"Subtle structural changes in the Asp251Gly\/Gln307His P450 BM3 mutant responsible for new activity toward diclofenac, tolbutamide and ibuprofen","volume":"602","author":"Di Nardo","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.btre.2019.e00372_bib0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nsb0297-140","article-title":"The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid","volume":"4","author":"Li","year":"1997","journal-title":"Nat. Struct. Biol."},{"issue":"Pt 2","key":"10.1016\/j.btre.2019.e00372_bib0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/bj3390371","article-title":"Roles of key active-site residues in flavocytochrome P450 BM3","volume":"339","author":"Noble","year":"1999","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.btre.2019.e00372_bib0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/dmd.110.036392","article-title":"Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants","volume":"39","author":"Kim","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"20","key":"10.1016\/j.btre.2019.e00372_bib0245","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1016\/j.bmc.2014.06.022","article-title":"Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs","volume":"22","author":"Venkataraman","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.btre.2019.e00372_bib0250","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2125.1997.t01-1-00605.x","article-title":"The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine","volume":"44","author":"Eiermann","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.btre.2019.e00372_bib0255","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000028333","article-title":"Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes","volume":"59","author":"Olesen","year":"1999","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.btre.2019.e00372_bib0260","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/cs5020404","article-title":"Chemo-, Regio-, and Stereoselective Oxidation of the Monocyclic Diterpenoid \u03b2-Cembrenediol by P450 BM3","volume":"5","author":"Le-Huu","year":"2015","journal-title":"ACS Catal."},{"issue":"30","key":"10.1016\/j.btre.2019.e00372_bib0265","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1021\/jacs.7b05196","article-title":"Enantioselective total synthesis of nigelladine a via late-stage C-H oxidation enabled by an engineered P450 enzyme","volume":"139","author":"Loskot","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.btre.2019.e00372_bib0270","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.bpj.2018.08.026","article-title":"Molecular determinants of substrate affinity and enzyme activity of a cytochrome P450BM3 variant","volume":"115","author":"Geronimo","year":"2018","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.btre.2019.e00372_bib0275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/bp060314b","article-title":"Substrate supply for effective biocatalysis","volume":"23","author":"Kim","year":"2007","journal-title":"Biotechnol. Prog."},{"issue":"5","key":"10.1016\/j.btre.2019.e00372_bib0280","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1073\/pnas.96.5.1863","article-title":"Structure of a cytochrome P450\u2013redox partner electron-transfer complex","volume":"96","author":"Sevrioukova","year":"1999","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Biotechnology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215017X19303868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215017X19303868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T10:27:09Z","timestamp":1610879229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215017X19303868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":56,"alternative-id":["S2215017X19303868"],"URL":"https:\/\/doi.org\/10.1016\/j.btre.2019.e00372","relation":{},"ISSN":["2215-017X"],"issn-type":[{"value":"2215-017X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of metabolites of the anti-cancer drug noscapine using a P450BM3 mutant library","name":"articletitle","label":"Article Title"},{"value":"Biotechnology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.btre.2019.e00372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"e00372"}}